Why the study?
Is readministration of abciximab safe and effective in patients undergoing percutaneous coronary intervention?
Population
n=500 consecutive patients receiving abciximab for at least a second time during percutaneous coronary…
Design
Cohort
Authors
Discussion
Loading...
Member takes
Implication
Requires platelet monitoring for abciximab readministration in PCI; leaves open randomized confirmation of safety.
Structured PICO
Is readministration of abciximab safe and effective in patients undergoing percutaneous coronary intervention?
P
Population
n=500 consecutive patients receiving abciximab for at least a second time during percutaneous coronary intervention at 22 centers in the United States.
I
Intervention
Abciximab readministration (at least a second time) during percutaneous coronary intervention
O
Outcome
Safety (incidence of hypersensitivity reactions, major bleeding, and thrombocytopenia) and efficacy (event-free clinical success)safety
Abciximab readministration during PCI is clinically successful and free of hypersensitivity or major bleeding, but is associated with a risk of profound thrombocytopenia requiring careful monitoring.
Cite This Study
Tcheng et al. (2001) studied this question.